Histologically proven NSCLC with nodal metastases: T1-3N2M0
Performance status 0-1
Patient medically fit enough for protocol therapy, including operability
Age 18-75
Written informed consent
No previous chemo- or radiotherapy
You may not be if
Patients with prior or concomitant malignancies Allowed are: non-melanomatous skin cancer, adequately treated in situ cervical cancer or any other neoplastic diseases with disease-free interval ³ 5 years.
Presence or history of any distant metastasis
Unstable cardiac disease requiring treatment, congestive heart failure or angina pectoris even if medically controlled, significant arrhythmia, or prior history of myocardial infarction in the last 3 months
History of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
Active uncontrolled infection
Uncontrolled diabetes mellitus
Gastric ulcers
Preexisting peripheral neuropathy (\> grade 1)
Other serious underlying medical condition which could impair the ability of the patient to participate in the trial
Concurrent treatment with other experimental drugs
Pretreatment with any other cytostatic therapy
Previous radiotherapy to the chest
Concurrent treatment with prednisone (or equivalent) except: for the prophylactic medication regimen before treatment, treatment of acute hypersensitivity reactions or chronic treatment (initiated \> 6 months prior to trial entry) at low dose (£ 20 mg methylprednisolone or equivalent)
Definite contraindications for the use of corticosteroids as premedication
Treatment within a clinical trial within 30 days prior to trial entry
Socioeconomic or geographic circumstances that may prohibit proper staging, treatment or follow-up procedures
Pregnancy, lactation period
Clareo Health | Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases
